On April 2, 2025 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, reported that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation (Press release, Curis, APR 2, 2025, View Source [SID1234651754]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All Bets on IRAK4 Fireside Chat:

Time: 4:30 pm ET (1:30 pm PT)
Fireside Chat Webcast
Curis Company Presentation:

Time: 5:00 pm ET (2:00 pm PT)
Corporate Presentation Webcast
The live webcast and archived replay will be available and can also be accessed from the Events & Presentations section of Curis’s website.